Physical Activity and Mortality in Type 2 Diabetes
1 other identifier
observational
502,682
0 countries
N/A
Brief Summary
The primary aim of study is to study the association between leisure-time physical activity and all-cause mortality among individuals with type 2 diabetes in the UK Biobank cohort and the China Kadoorie Biobank cohort. Secondary outcomes are CVD-mortality (both cohorts) and risk of major adverse cardiovascular events (UK Biobank only). Secondary exposures are physical activity from transportation and occupation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2006
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2021
CompletedFirst Submitted
Initial submission to the registry
May 5, 2022
CompletedFirst Posted
Study publicly available on registry
May 18, 2022
CompletedMay 18, 2022
May 1, 2022
15.6 years
May 5, 2022
May 15, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
All-cause mortality
Mortality status optained from registries. The longest available follow-up from baseline examination will be used. Deaths during the first 3 years will be left-censored.
Through longest available follow-up, up to 14.5 years (UK Biobank)
All-cause mortality
Mortality status optained from registries. The longest available follow-up from baseline examination will be used. Deaths during the first 3 years will be left-censored.
Through longest available follow-up, up to 12.4 years (China Kadoorie Biobank)
Secondary Outcomes (2)
Cardiovascular mortality
Through longest available follow-up, up to 14.5 (UK Biobank) and 0.4 (China Kadoorie Biobank) years
Major adverse cardiovascular events (MACE)
Through longest available follow-up, up to 14.5 (UK Biobank only)
Study Arms (1)
Individuals with type 2 diabetes at the baseline examination
UK Biobank: Prevalent type 2 diabetes is determined by the algorithm of Eastwood et al. (6) or from measured Hba1c ≥48 mmol/mol. China Kadoorie Biobank: prevalent type 2 diabetes is based on self-reported current diabetes with a diagnosis age above 30 years, a random plasma blood glucose ≥11.1 mmol/L, or fasting plasma blood glucose ≥7.0 mmol/L.
Interventions
Self-reported leisure-time physical activity, categorized as; zero (reference), \>0-7.49 MET-hrs/week, 7.5-14.9 MET-hrs/week, or ≥15 MET-hrs/week.
Eligibility Criteria
See statistical analysis plan
You may qualify if:
- UK Biobank: Prevalent type 2 diabetes is determined by the algorithm by Eastwood (PMID: 27631769) or from measured Hba1c ≥48 mmol/mol.
- China Kadoorie Biobank: Self-reported current diabetes with a diagnosis age above 30 years, a random plasma blood glucose ≥11.1 mmol/L, or fasting plasma blood glucose ≥7.0 mmol/L
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Aarhus University Hospitallead
- University of Aarhuscollaborator
- The Danish Diabetes Associationcollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 5, 2022
First Posted
May 18, 2022
Study Start
March 1, 2006
Primary Completion
October 1, 2021
Study Completion
October 30, 2021
Last Updated
May 18, 2022
Record last verified: 2022-05